A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
← catalyst calendarNCT07037875 · readout ≤ 11 d
Sponsored by Cinclus Pharma Holding AB (industry) · CINPHA.ST — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
500estimated
Sites
87
Countries
Bulgaria, Czechia, Georgia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-11 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- GERD (Gastroesophageal Reflux Disease)
Interventions
- Drug: Linaprazan glurate 50 mg Twice Daily (BID)
- Drug: Linaprazan Glurate 50 mg Once Daily (QD)
- Drug: Lansoprazole 30 mg Once Daily (QD)
Primary outcome
what the primary-completion date above is the date OFHealing of EE at Week 4 as assessed by endoscopy in participants with Baseline EE LA grades C/D.
measured From enrollment to the end of treatment at 4 weeks.
Permalink · CINPHA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed